- Home
- Research
- Mental Health
- Trends in new psychoactive substance poisonings in the Netherlands: A 14-year retrospective analysis (2012-2025).
Dutch poison centers track surge in synthetic drug poisonings
Trends in new psychoactive substance poisonings in the Netherlands: A 14-year retrospective analysis (2012-2025).
AI Summary
This study analyzed 14 years of poison center data from the Netherlands, tracking how reported poisonings from new psychoactive substances (NPS) have evolved from 2012 to 2025. Researchers examined 4,289 NPS-related poisoning cases out of 19,316 total recreational drug poisonings. The findings reveal a troubling trend: NPS poisonings increased dramatically by 19% each year, with cases jumping from just 32 in 2012 to 829 in 2025. The diversity of substances involved also exploded, with healthcare workers documenting exposure to 176 different NPS by 2025, compared to only 17 in 2012.
The composition of NPS poisonings shifted significantly over time, with three categories dominating cases: cathinones (synthetic stimulants), phenethylamines (hallucinogens), and benzodiazepines (sedatives) together accounting for 83% of all NPS poisonings. The most frequently reported substances included 3-methylmethcathinone, bromazolam, 4-fluoroamphetamine, and 2C-B, each representing 5-22% of cases. Notably, cannabinoid-related NPS poisonings remained rare, occurring in less than 5% of all cases, suggesting they are not a major driver of NPS-related hospitalizations in this surveillance system.
The data demonstrates a rapidly evolving landscape of synthetic drug threats in Europe. The peak reported poisonings in July and December suggest seasonal patterns in NPS use, possibly linked to holiday periods and summer events. For cannabis users and public health officials, this research underscores the importance of understanding broader synthetic drug trendsβwhile synthetic cannabinoids appear less prominent in poisoning reports, the overall explosion in NPS diversity highlights the unpredictable dangers of unregulated novel substances compared to established cannabis markets.
π
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Review describes AHC and reports cannabidiol as an additional treatment option
Review finds school prevention often covers cannabis, but evidence gaps remain
Antipsychotics eased symptoms, but relapse-prevention evidence remains thin
Explore More Research
Stay informed about the latest cannabis science.